Title | Authors | Date | Link |
---|---|---|---|
Assessing the Preparedness of the Australian Health Care System Infrastructure for an Alzheimer's Disease-Modifying Therapy | Sangita M. Baxi, Federico Girosi, Jodi L. Liu | 2019 | |
Assessing the Preparedness of the Canadian Health Care System Infrastructure for an Alzheimer's Treatment | Jodi L. Liu, Jakub P. Hlavka, Daniel T. Coulter, Sangita M. Baxi, Soeren Mattke, Courtney A. Gidengil | 2019 | |
Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment | Jakub P. Hlavka, Soeren Mattke, Jodi L. Liu | 2018 | |
Assessing the Preparedness of the Japanese Health Care System Infrastructure for an Alzheimer’s Treatment | Soeren Mattke, Jakub P. Hlávka, Joanne Yoong, Mo Wang, Rei Goto | 2019 | |
Assessing the Preparedness of the Korean Healthcare System Infrastructure for an Alzheimer’s Treatment | Hankyung Jun, Sang Kyu Cho, Joanne Yoong, Soeren Mattke | 2020 | |
Assessing the Preparedness of the Taiwanese Healthcare System Infrastructure for an Alzheimer’s Treatment | Hankyung Jun, Sang Kyu Cho, Joanne Yoong, Oliver Yuen, Soeren Mattke | 2021 | |
Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer's disease treatment | Jenny Lam, Hankyung Jun, Sang Kyu Cho, Mark Hanson, Soeren Mattke | 2021 | |
Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times | Soeren Mattke, Sang Kyu Cho, Tobias Bittner, Jakub Hlávka, Mark Hanson | 2020 | |
The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey | Jenny Lam, Jakub Hlávka and Soeren Mattke | 2019 |
Title | Authors | Date | Link |
---|---|---|---|
Implications of Alzheimer’s Treatment for Organization and Payment of Medical Practices in the EU-5 Countries | Soeren Mattke, Andreas Ullrich and Mo Wang | 2020 | |
Implications of Alzheimer’s Treatment for Organization and Payment of Medical Practices in the United States | Soeren Mattke and Mo Wang | 2020 | |
Implications of Alzheimer’s Treatment for Organization and Payment of Medical Practices in Canada | Soeren Mattke and Mo Wang | 2021 | |
Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer's disease treatment | Jenny Lam, Hankyung Jun, Sang Kyu Cho, Mark Hanson, Soeren Mattke | 2021 | |
The Predicted Long-Term Benefits of Ensuring Timely Treatment and Medication Adherence in Early Schizophrenia | Marcela Horvitz-Lennon, Zachary Predmore, Patrick Orr, Mark Hanson, Richard Hillestad, Mike Durkin, Antoine C El Khoury, Soeren Mattke | 2019 | |
Potential Benefits to Patients and Payers From Increased Measurement of Antipsychotic Plasma Levels in the Management of Schizophrenia | Zachary Predmore, Soeren Mattke, Marcela Horvitz-Lennon | 2018 | |
Improving Antipsychotic Adherence Among Patients With Schizophrenia: Savings for States | Zachary S. Predmore, Soeren Mattke, Marcela Horvitz-Lennon | 2015 |
Title | Authors | Date | Link |
---|---|---|---|
Estimating minimal clinically important differences for two scales in patients with chronic traumatic brain injury | Soeren Mattke, Steven C. Cramer, Mo Wang, Janet Prvu Bettger, Kevin M.Cockroft, Wuwei Feng, Michael Jaffee, Tolu O. Oyesanya, Ava M. Puccio,Nancy Temkin, Carolee Winstein, Steven L. Wolf, and Michael R. Yochelson | 2020 | |
Evidence for Misspecification of a Nationally Used Quality Measure for Substance Use Treatment | Soeren Mattke, Zachary Predmore, Elizabeth Sloss, Asa Wilks, Katherine E Watkins | 2018 | |
Potential Benefits to Patients and Payers From Increased Measurement of Antipsychotic Plasma Levels in the Management of Schizophrenia | Zachary Predmore, Soeren Mattke, Marcela Horvitz-Lennon | 2018 |
Title | Authors | Date | Link |
---|---|---|---|
Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer's disease treatment | Jenny Lam, Hankyung Jun, Sang Kyu Cho, Mark Hanson, Soeren Mattke | 2021 | |
Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times | Soeren Mattke, Sang Kyu Cho, Tobias Bittner, Jakub Hlávka, Mark Hanson | 2020 | |
How Much Value Would a Treatment for Alzheimer's Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy | Hankyung Jun, Sang K Cho, Elmar R Aliyev, Soeren Mattke, Sze-Chuan Suen | 2020 | |
The Predicted Long-Term Benefits of Ensuring Timely Treatment and Medication Adherence in Early Schizophrenia | Marcela Horvitz-Lennon, Zachary Predmore, Patrick Orr, Mark Hanson, Richard Hillestad, Mike Durkin, Antoine C El Khoury, Soeren Mattke | 2019 | |
Simulated long-term outcomes of early use of long-acting injectable antipsychotics in early schizophrenia | Marcela Horvitz-Lennon, Zachary Predmore, Patrick Orr, Mark Hanson, Richard Hillestad, Mike Durkin, Edward Kim, Soeren Mattke | 2018 | |
Potential Benefits to Patients and Payers From Increased Measurement of Antipsychotic Plasma Levels in the Management of Schizophrenia | Zachary Predmore, Soeren Mattke, Marcela Horvitz-Lennon | 2018 | |
Improving Antipsychotic Adherence Among Patients With Schizophrenia: Savings for States | Zachary S. Predmore, Soeren Mattke, Marcela Horvitz-Lennon | 2015 |
Title | Authors | Date | Link |
---|---|---|---|
Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times | Soeren Mattke, Sang Kyu Cho, Tobias Bittner, Jakub Hlávka, Mark Hanson | 2020 | |
How Much Value Would a Treatment for Alzheimer's Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy | Hankyung Jun, Sang K Cho, Elmar R Aliyev, Soeren Mattke, Sze-Chuan Suen | 2020 | |
Simulated long-term outcomes of early use of long-acting injectable antipsychotics in early schizophrenia | Marcela Horvitz-Lennon, Zachary Predmore, Patrick Orr, Mark Hanson, Richard Hillestad, Mike Durkin, Edward Kim, Soeren Mattke | 2018 | |
Potential Benefits to Patients and Payers From Increased Measurement of Antipsychotic Plasma Levels in the Management of Schizophrenia | Zachary Predmore, Soeren Mattke, Marcela Horvitz-Lennon | 2018 | |
The Role of Antipsychotic Plasma Levels in the Treatment of Schizophrenia | Marcela Horvitz-Lennon, Soeren Mattke, Zachary Predmore, Oliver D. Howes | 2017 |